OBI-904 / OBI Pharma - LARVOL DELTA

OBI-904, a glycan-based site-specific Nectin-4-targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcoming EV-resistance in non-clinical studies (AACR 2026) - "Antitumor activity was tested in CDX models of HNSCC, CRC, TNBC, prostate cancer, cholangiocarcinoma, and in PDX models of cervical and sarcoma, as well as in an EV-resistant bladder CDX model, with Padcev and ETx-22 as benchmarks. OBI-904, a next-generation Nectin-4-targeted ADC with optimized stability and payload delivery, demonstrated potent antitumor activity across multiple models, including EV-resistant tumors, independent of Nectin-4 expression. Favorable pharmacokinetics and toxicology support its further clinical development as a promising therapy for Nectin-4-expressing cancers."

ADC • Clinical • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Oncology • Prostate Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • NECTIN4

OBI-904, a next-generation nectin-4-targeting exatecan ADC, demonstrates enhanced cytotoxicity and overcomes enfortumab vedotin resistance (AACR 2026) - "Importantly, OBI-904 retained strong cytotoxic activity in P-gp-overexpressing and EV-resistant tumor cells.Collectively, these findings establish OBI-904 as a potent, next-generation Nectin-4 ADC with reduced skin binding, enhanced cytotoxicity, a pronounced bystander effect, and the ability to overcome P-gp-mediated and EV-acquired resistance. These attributes position OBI-904 as a promising clinical candidate with the potential to achieve improved therapeutic outcomes in Nectin-4-expressing cancers."

ADC • Oncology • NECTIN4

Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index (AACR 2025) - "In preclinical models, OBI-902 (TROP2 GlycOBI® DAR4 ADC) and OBI-904 (Nectin-4 GlycOBI® DAR8 ADC), both using Exatecan, a potent topoisomerase 1 inhibitor as the payload, have demonstrated promising antitumor activities. The integration of glycan engineering, EndoSymeOBI®, and a novel linker design establishes the GlycOBI® suite of technologies as a robust and adaptable solution to address the current ADC limitations. These advancements underscore its transformative potential in driving the next generation of therapeutics."

Oncology • NECTIN4